In addition, a post-hoc analysis of the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL) study revealed that an achieved SBP < 140 mmHg was associated with a decreased risk of renal endpoint, defined as a composite of doubling of serum creatinine, kidney failure with replacement therapy, or death [24]. The gene discussed is AGT; the disease is type 1 diabetes mellitus.